WuXi Biologics added to FTSE4Good Index Series for sixth straight yearPUBT·2 days ago, 09:28 PMWXXWY+1.34%02269+2.49%
WuXi Biologics Recognized by FTSE4Good for the Sixth Consecutive Year, Underscoring Value Creation Through Green CRDMOPR Newswire·2 days ago, 09:27 PMWXXWY+1.34%02269+2.49%
Akeso doses first patient in Phase Ib/II NSCLC trial of HER3 ADC AK138D1 with ivonescimabPUBT·Jul 27 at 09:36 PM09926+0.80%
Sino Biopharmaceutical Forms Indonesia Joint Venture With Tempo ScanTip Ranks·Jul 27 at 04:11 AM01177-0.59%
Nomura Raises WUXI BIO TP to HKD51.38, Estimates 1H Profit to Drop 15%AASTOCKS News·Jul 27 at 02:22 AMWXXWY+1.34%02269+2.49%
Nomura Expects AKESO to Swing to Interim Profit of RMB46M, Maintains Buy RatingAASTOCKS News·Jul 26 at 11:59 PM09926+0.80%
Chinese biotech overtakes AI as emerging-market growth tradeBusinesstimes News·Jul 26 at 10:14 PM300765+5.61%AZN-0.60%
Akeso grants 3,603,500 share options at HK$ 99.5 exercise price under employee incentive planPUBT·Jul 26 at 06:52 AM09926+0.80%
Sino Biopharmaceutical (SBMFF) Receives a Buy from UOB Kay HianTip Ranks·Jul 25 at 09:55 AM01177-0.59%
WuXi Biologics schedules board meeting to review interim resultsPUBT·Jul 24 at 03:32 AMWXXWY+1.34%02269+2.49%
Summit Updates Ivonescimab OS Data and US FDA Review TimingCoinLive·Jul 23 at 09:52 AMSMMT-1.60%09926+0.80%
